Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington'S Disease: Clinical Consequences and Therapeutic Implications

Reviews in the Neurosciences

Volumn 18, Issue 3-4, 2007, Pages 223-252

  Aziz, N A ^a   Swaab, D F ^b   Pijl, H ^a   Roos, R A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

autonomic nervous system; body weight; endocrine system; Huntington's disease; hypothalamus; metabolism; neuropeptides; sleep

Indexed keywords

ALPHA INTERMEDIN; CORTICOTROPIN RELEASING FACTOR; GHRELIN; GONADORELIN; HISTAMINE; LEPTIN; NEUROPEPTIDE; NEUROTENSIN; OREXIN; PROTIRELIN; SOMATOSTATIN;

AUTONOMIC NEUROPATHY; BASAL METABOLIC RATE; BODY WEIGHT; CARBOHYDRATE METABOLISM; ENERGY EXPENDITURE; FAMILIAL AMYLOID POLYNEUROPATHY; HUMAN; HUNTINGTON CHOREA; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMO PITUITARY GONADAL AXIS; HYPOTHALAMO PITUITARY THYROID AXIS; HYPOTHALAMUS DISEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LACTOTROPIC AXIS; LIPID METABOLISM; METABOLIC DISORDER; NEUROENDOCRINE DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SOMATOTROPIC AXIS; WEIGHT REDUCTION;

ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; ENDOCRINE SYSTEM DISEASES; HUMANS; HUNTINGTON DISEASE; HYPOTHALAMIC DISEASES; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; METABOLIC DISEASES; NEUROSECRETORY SYSTEMS; SLEEP DISORDERS;

EID: 36549030256     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.2007.18.3-4.223     Document Type: Article

References (237)

1. Alkemade A, Friesema EC, Unmehopa UA, Fabriek BO, Kuiper GG, Leonard JL, et al. Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus. J Clin Endocrinol Metab 2005; 90: 4322-2334.
2. Aminoff MJ, Gross M. A study of vasomotor function in patients with Huntington's chorea. Clin Sci Mol Med 1973; 45: 20P.
3. Aminoff MJ, Gross M. Vasoregulatory activity in patients with Huntington's chorea. J Neurol Sci 1974; 21: 33-38.
4. Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, et al. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 2002; 11: 410-424.
5. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. NeuroReport 2001; 12: 3371-3373.
6. Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, et al. Autonomic nervous system function in Huntington's disease. J Neurol Neurosurg Psychiatry 2002; 72: 726-731.
7. Aronin N, Cooper PE, Lorenz LJ, Bird ED, Sagar SM, Leeman SE, et al. Somatostatin is increased in the basal ganglia in Huntington disease. Ann Neurol 1983; 13: 519-526.
8. Bao AM, Hestiantoro A, Van Someren EJ, Swaab DF, Zhou JN. Colocalization of corticotropin-releasing hormone and oestrogen receptor-alpha in the paraventricular nucleus of the hypothalamus in mood disorders. Brain 2005; 128: 1301-1313.
9. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003; 361: 1642-1644.
10. Baumann CR, Hersberger M, Bassetti CL. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J Neurol 2006; 253: 1232-1233.
11. Beal MF, Bird ED, Langlais PJ, Martin JB. Somatostatin is increased in the nucleus accumbens in Huntington's disease. Neurology 1984; 34: 663-666.
12. Beal MF, Martin JB. Neuropeptides in neurological disease. Ann Neurol 1986; 20: 547-565.
13. Beal MF, Mazurek MF, Ellison DW, Swartz KJ, McGarvey U, Bird ED, et al. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann Neurol 1988; 23: 562-569.
14. Bernheimer H, Homykiewicz O. Brain amines in Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology. New York: Raven Press, 1973; 525-531.
15. Beverstock GC. The current state of research with peripheral tissues in Huntington disease. Hum Genet 1984; 66: 115-131.
16. Beverstock GC, Pearson PL. Membrane fluidity measurements in peripheral cells from Huntington's disease patients. J Neurol Neurosurg Psychiatry 1981; 44: 684-689.
17. Bird ED. Neuoendocrine changes in Huntington's disease - an overview. In: Chase TN, Wexler NS, Barbeau A, eds. Advances in Neurology. New York: Raven Press, 1979; 291-297.
18. Bird ED, Chiappa SA, Fink G. Brain immunoreactive gonadotropin-releasing hormone in Huntington's chorea and in non-choreic subjects. Nature 1976; 260: 536-538.
19. Bjorkqvist M, Fex M, Renstrom E, Wierup N, Petersen A, Gil J, et al. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 2005; 14: 565-574.
20. Bjorkqvist M, Petersen A, Bacos K, Isaacs J, Norlen P, Gil J, et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum Mol Genet 2006; 15: 1713-1721.
21. Bjorkqvist M, Petersen A, Nielsen J, Ecker D, Mulder H, Hayden M, et al. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin Genet 2006; 70: 78-79.
22. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA 2006; 103: 4246-4251.
23. Borri P, Hooghwinkel GJ, Bruyn G. Biochemical studies in Huntington's chorea. 4. The fatty acid composition of plasma and erythrocyte lipids. Psychiatr Neurol Neurochir 1966; 69: 143-148.
24. Bots GT, Bruyn GW. Neuropathological changes of the nucleus accumbens in Huntington's chorea. Acta Neuropathol (Berl) 1981; 55: 21-22.
25. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001; 63: 637-672.
26. Browne SE, Beal MF. The energetics of Huntington's disease. Neurochem Res 2004; 29: 531-546.
27. Bruyn GW. Biochemical studies in Huntington's chorea. 3. Aminoacids in serum and urine. Psychiatr Neurol Neurochir 1966; 69: 139-142.
28. Bruyn GW. Huntington's chorea. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam: North-Holland Publishing Co, 1968; 298-378.
29. Bruyn GW. Neuropathological changes in Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology. New York: Raven Press, 1973; 399-403.
30. Bruyn GW, de Jong FH. Dehydroepiandrosterone-sulfate and Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology. New York: Raven Press, 1973; 553-555.
31. Bruyn GW, de Jong FH, van der Molen JH. Huntington's chorea and the adrenal. Br Med J 1972; 1(798): 506.
32. Buruma OJ, Van der KW, Barendswaard EC, Roos RA, Kromhout D, Van der Velde EA. Which factors influence age at onset and rate of progression in Huntington's disease? J Neurol Sci 1987; 80: 299-306.
33. Caine E, Kartzinel R, Ebert M, Carter AC. Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release. Life Sci 1978; 22: 911-918.
34. Camerlingo M, Bottacchi E, Gambaro P, D'Alessandro G, Carenini L, Mamoli A. Parasympathetic function in Huntington's disease. Funct Neurol 1987; 2: 227-230.
35. Caraceni T, Panerai AE, Paratl EA, Cocchi D, Muller EE. Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea. J Clin Endocrinol Metab 1977; 44: 870-875.
36. Chalmers RJ, Johnson RH, Keogh HJ, Nanda RN. Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea. J Neurol Neurosurg Psychiatry 1978; 41: 135-139.
37. Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci USA 2005; 102: 12218-12223.
38. Chase TN. Biochemical and pharmacological studies of monoamines in Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology. New York: Raven Press, 1973; 533-542.
39. Chokroverty S. Sleep and degenerative neurologic disorders. Neurol Clin 1996; 14: 807-826.
40. Christofides J, Bridel Mv, Egerton M, Mackay GM, Forrest CM, Stoy N, et al. Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury. J Neurochem 2006; 97: 1078-1088.
41. Clark AW, Parhad IM, Folstein SE, Whitehouse PJ, Hedreen JC, Price DL, et al. The nucleus basalis in Huntington's disease. Neurology 1983; 33: 1262-1267.
42. Clifford JJ, Drago J, Natoli AL, Wong JY, Kinsella A, Waddington JL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002; 109: 81-88.
43. Cowie V, Seakins JW. Urinary alanine excretor in a Huntington's chorea family. J Ment Sci 1962; 108: 427-431.
44. Cui H, Cai F, Belsham DD. Anorexigenic hormones leptin, insulin, and alpha-melanocyte-stimulating hormone directly induce neurotensin (NT) gene expression in novel NT-expressing cell models. J Neurosci 2005; 25: 9497-9506.
45. Dagogo-Jack S, Tykodi G, Umamaheswaran I. Inhibition of Cortisol biosynthesis decreases circulating leptin levels in obese humans. J Clin Endocrinol Metab 2005; 90: 5333-5335.
46. Das UN, Vaddadi KS. Essential fatty acids in Huntington's disease. Nutrition 2004; 20: 942-947.
47. Davidson MB, Green S, Menkes JH. Normal glucose, insulin and growth hormone responses to oral glucose in Huntington's disease. J Lab Clin Med 1974; 84: 807-812.
48. Dawbarn D, De Quidt ME, Emson PC. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res 1985; 340: 251-260.
49. de Souza EB, Whitehouse PJ, Folstein SE, Price DL, Vale WW. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease. Brain Res 1987; 437: 355-349.
50. Den Heijer JC, Bollen WL, Reulen JP, van Dijk JG, Kramer CG, Roos RA, et al. Autonomic nervous function in Huntington's disease. Arch Neurol 1988; 45: 309-312.
51. Destee A, Petit H, Fossati P, Warot P. Huntington's chorea and somatotropic hormone: dynamic explorations in 27 cases [in French]. Rev Neurol (Paris) 1981; 137: 21-31.
52. Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in early stage of Huntington's disease. Neurology 2002; 59: 1325-1330.
53. Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 2003; 100: 2911-2916.
54. Durso R, Ruggeri SA, Denaro A, Tamminga CA. Neuroendocrine studies in Huntington's disease. In: Shah NS, Donald AG, eds. Psychoneuroendocrine Dysfunction. New York: Springer, 1984; 209-230.
55. Durso R, Tamminga CA, Denaro A, Ruggeri S, Chase TN. Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease. Neurology 1983; 33: 1229-1232.
56. Durso R, Tamminga CA, Ruggeri S, Denaro A, Kuo S, Chase TN. Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease. J Neurol Neurosurg Psychiatry 1983; 46: 1134-1137.
57. Ellison DW, Beal MF, Martin JB. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease. Brain Res 1987; 417: 389-392.
58. Emser W, Brenner M, Stober T, Schimrigk K. Changes in nocturnal sleep in Huntington's and Parkinson's disease. J Neurol 1988; 235: 177-179.
59. Esel E, Kartalci S, Tutus A, Turan T, Sofuoglu S. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 303-309.
60. Fain JN, Del Mar NA, Meade CA, Reiner A, Goldowitz D. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum Mol Genet 2001; 10: 145-152.
61. Farrer LA. Diabetes mellitus in Huntington disease. Clin Genet 1985; 27: 62-67.
62. Farrer LA, Meaney FJ. An anthropometric assessment of Huntington's disease patients and families. Am J Phys Anthropol 1985; 67: 185-194.
63. Farrer LA, Yu PL. Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease. Am J Med Genet 1985; 21: 307-316.
64. Fedoroff JP, Peyser C, Franz ML, Folstein SE. Sexual disorders in Huntington's disease. J Neuropsychiatry Clin Neurosci 1994; 6: 147-153.
65. Fennema-Notestine C, Archibald SL, Jacobson MW, Corey-Bloom J, Paulsen JS, Peavy GM, et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004; 63: 989-995.
66. Fish DR, Sawyers D, Allen PJ, Blackie JD, Lees AJ, Marsden CD. The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. Arch Neurol 1991; 48: 210-214.
67. Fliers E, Kreier F, Voshol PJ, Havekes LM, Sauerwein HP, Kalsbeek A, et al. White adipose tissue: getting nervous. J Neuroendocrinol 2003; 15: 1005-1010.
68. Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN. Energy balance in early-stage Huntington disease. Am J Clin Nutr 2005; 81: 1335-1341.
69. Gaus SE, Lin L, Mignot E. CSF hypocretin levels are normal in Huntington's disease patients. Sleep 2005; 28: 1607-1608.
70. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003; 184: 1010-1016.
71. Gillies G. Somatostatin: the neuroendocrine story. Trends Pharmacol Sci 1997; 18: 87-95.
72. Goodchild RE, Court JA, Hobson I, Piggott MA, Perry RH, Ince P, et al. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Eur J Neurosci 1999; 11: 449-456.
73. Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J. Rate and correlates of weight change in Huntington's disease. J Neurol Neurosurg Psychiatry 2004; 75: 209-212.
74. Harper P. Huntington's Disease. London: W.B. Saunders Co. Ltd., 1996.
75. Hayden MR, Vinik AI. Disturbances in hypothalamicpituitary hormonal dopaminergic regulation in Huntington's disease. In: Chase TN, Wexler NS, Barbeau A, eds. Advances in Neurology. New York: Raven Press, 1979; 305-317.
76. Hayden MR, Vinik AI, Paul M, Beighton P. Impaired prolactin release in Huntington's chorea. Evidence for dopaminergic excess. Lancet 1977; ii: 423-426.
77. Hebb MO, Denovan-Wright EM, Robertson HA. Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats. FASEB J 1999; 13: 1099-1106.
78. Heinrichs SC, Lapsansky J, Behan DP, Chan RK, Sawchenko PE, Lorang M, et al. Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proc Natl Acad Sci USA 1996; 93: 15475-15480.
79. Heuser IJ, Chase TN, Mouradian MM. The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease. Biol Psychiatry 1991; 30: 943-952.
80. Hooghwinkel GJ, Borri PF, Bruyn GW. Biochemical studies in Huntington's chorea. II. Composition of blood lipids. Acta Neurol Scand 1966; 42: 213-220.
81. Hoybye C, Hilding A, Jacobsson H, Thoren M. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2003; 58: 653-661.
82. Hunt MJ, Morton AJ. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 2005; 166: 220-229.
83. Huntington G. On Chorea. Philadelphia, PA: The Medical and Surgical Reporter, 1872; 317-321.
84. Hurelbrink CB, Lewis SJ, Barker RA. The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease. J Neurol 2005; 252: 642-647.
85. Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, Freed CR. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 1999; 48: 649-651.
86. Iakhno NN. [Disorders of nocturnal sleep in Huntington chorea], Zh Nevropatol Psikhiatr Im S S Korsakova 1985; 85: 340-346.
87. Jakel RJ, Maragos WF. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci 2000; 23: 239-245.
88. Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 2000; 74: 2108-2119.
89. Jobst EE, Enriori PJ, Cowley MA. The electrophysiology of feeding circuits. Trends Endocrinol Metab 2004; 15: 488-499.
90. Joseph-Bravo P. Hypophysiotropic thyrotropin-releasing hormone neurons as transducers of energy homeostasis. Endocrinology 2004; 145: 4813-4815.
91. Kagel MC, Leopold NA. Dysphagia in Huntington's disease: a 16-year retrospective. Dysphagia 1992; 7: 106-114.
92. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100.
93. Karydis I, Tolis G. Orexis, anorexia, and thyrotropin-releasing hormone. Thyroid 1998; 8: 947-950.
94. Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004; 75: 213-220.
95. Katsuno M, Adachi H, Sobue G. Sweet relief for Huntington disease. Nat Med 2004; 10: 123-124.
96. Kelley AE, Baldo BA, Pratt WE, Will MJ. Corticostriatal-hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav 2005; 86: 773-795.
97. Keogh HJ, Johnson RH, Nanda RN, Sulaiman WR. Altered growth hormone release in Huntington's chorea. J Neurol Neurosurg Psychiatry 1976; 39: 244-248.
98. Kirkpatrick B, Tamminga CA. The endocrinology of extrapyramidal system disorders. Neurol Clin 1988; 6: 159-172.
99. Kirkwood SC, Su JL, Conneally P, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol 2001; 58: 273-278.
100. Kobal J, Meglic B, Mesec A, Peterlin B. Early sympathetic hyperactivity in Huntington's disease. Eur J Neurol 2004; 11: 842-848.
101. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
102. Kok SW, Meinders AE, Overeem S, Lammers GJ, Roelfsema F, Frolich M, et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab 2002; 87: 805-809.
103. Kok SW, Roelfsema F, Overeem S, Lammers GJ, Frolich M, Meinders AE, et al. Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. Am J Physiol Endocrinol Metab 2005; 288: E892-E899.
104. Kok SW, Roelfsema F, Overeem S, Lammers GJ, Strijers RL, Frolich M, et al. Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. J Clin Endocrinol Metab 2002; 87: 5085-5091.
105. Konagaya Y, Konagaya M. [Abnormality of hypothalamic dopaminergic system in neuro-degenerative diseases-evaluation of alpha-melanocyte-stimulating hormone-like immunoreactivity in cerebrospinal fluid]. Rinsho Shinkeigaku 1991; 31: 821-825.
106. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997; 41: 160-165.
107. Kotliarova S, Jana NR, Sakamoto N, Kurosawa M, Miyazaki H, Nekooki M, et al. Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J Neurochem 2005; 93: 641-653.
108. Kreier F, Kalsbeek A, Ruiter M, Yilmaz A, Romijn JA, Sauerwein HP, et al. Central nervous determination of food storage-a daily switch from conservation to expenditure: implications for the metabolic syndrome. Eur J Pharmacol 2003; 480: 51-65.
109. Kreier F, Kap YS, Mettenleiter TC, van Heijningen C, van der Vliet J, Kalsbeek A, et al. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology 2006; 147: 1140-1147.
110. Kreier F, Yilmaz A, Kalsbeek A, Romijn JA, Sauerwein HP, Fliers E, et al. Hypothesis: shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome. Diabetes 2003; 52: 2652-2656.
111. Kremer HP, Kremer GH. Demise of a neuronal population in Huntington's disease and the importance of hyponeuronogenesis. Clin Neurol Neurosurg 1992; 94 (Suppl): S7-S8.
112. Kremer HP, Roos RA. Weight loss in Huntington's disease. Arch Neurol 1992; 49: 349.
113. Kremer HP, Roos RA, Dingjan G, Marani E, Bots GT. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 1990; 49: 371-382.
114. Kremer HP, Roos RA, Dingjan GM, Bots GT, Bruyn GW, Hofman MA. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett. 1991; 132: 101-104.
115. Kremer HP, Roos RA, Frolich M, Radder JK, Nieuwenhuijzen Kruseman AC, van der Vliet J, et al. Endocrine functions in Huntington's disease. A two-and-a-half years follow-up study. J Neurol Sci 1989; 90: 335-344.
116. Kurlan R, Caine E, Rubin A, Nemeroff CB, Bissette G, Zaczek R, et al. Cerebrospinal fluid correlates of depression in Huntington's disease. Arch Neurol 1988; 45: 881-883.
117. Lakowicz JR, Sheppard JR. Fluorescence spectroscopic studies of Huntington fibroblast membranes. Am J Hum Genet 1981; 33: 155-165.
118. Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS. Conditions associated with Huntington's disease at death. A case-control study. Arch Neurol 1988; 45: 878-880.
119. Lanska DJ, Lavine L, Lanska MJ, Schoenberg BS. Huntington's disease mortality in the United States. Neurology 1988; 38: 769-772.
120. Lavin PJ, Bone I, Sheridan P. Studies of hypothalamic function in Huntington's chorea. J Neurol Neurosurg Psychiatry 1981; 44: 414-418.
121. Leblhuber F, Haller H, Steiner K, Fuchs D. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled trial. Neurology 2004; 62: 1030.
122. Leblhuber F, Peichl M, Neubauer C, Reisecker F, Steinparz FX, Windhager E, et al. Serum dehydroepiandrosterone and Cortisol measurements in Huntington's chorea. J Neurol Sci 1995; 132: 76-79.
123. Leblhuber F, Walli J, Jellinger K, Tilz GP, Widner B, Laccone F, et al. Activated immune system in patients with Huntington's disease. Clin Chem Lab Med 1998; 36: 747-750.
124. Leopold NA, Kagel MC. Dysphagia in Huntington's disease. Arch Neurol 1985; 42: 57-60.
125. Leopold NA, Podolsky S. Exaggerated growth hormone response to arginine infusion in Huntington's disease. J Clin Endocrinol Metab 1975; 41: 160-163.
126. Levy CL, Carlson HE, Sowers JR, Goodlett RE, Tourtellotte WW, Hershman JM. Growth hormone and prolactin secretion in Huntington's disease. Life Sci 1979; 24: 743-749.
127. Li SH, Yu ZX, Li CL, Nguyen HP, Zhou YX, Deng C, et al. Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J Neurosci 2003; 23: 6956-6964.
128. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72-76.
129. Luesse HG, Schiefer J, Spruenken A, Puls C, Block F, Kosinski CM. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav Brain Res 2001; 126: 185-195.
130. Magrani J, de Castro e Silva E, Ramos AC, Athanazio R, Barbetta M, Fregoneze JB. Central H1 and H2 receptor participation in the control of water and salt intake in rats. Physiol Behav 2005; 84: 233-243.
131. Maltese WA. Cholesterol synthesis in cultured skin fibroblasts from patients with Huntington's disease. Biochem Med 1984; 32: 144-150.
132. Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann Neurol 2005; 57: 520-525.
133. Martinez-Mir MI, Pollard H, Moreau J, Traiffort E, Ruat M, Schwartz JC, et al. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse 1993; 15: 209-220.
134. Masaki T, Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol Sci 2006; 27: 279-284.
135. Mattson B, Persson SA. Cerebrospinal fluid 5-HIAA levels in Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology. New York: Raven Press, 1973; 557-558.
136. Mazurek MF, Garside S, Beal MF. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann Neurol 1997; 41: 540-547.
137. Meier A, Mollenhauer B, Cohrs S, Rodenbeck A, Jordan W, Meller J, et al. Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease. Brain Res 2005; 1063: 201-203.
138. Menalled L, Zanjani H, MacKenzie L, Koppel A, Carpenter E, Zeitlin S, et al. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol 2000; 162: 328-342.
139. Menkes JH, Hanoch A. Huntington's disease-growth of fibroblast cultures in lipid-deficient medium: a preliminary report. Ann Neurol 1977; 1: 423-425.
140. Morales LM, Estevez J, Suarez H, Villalobos R, Chacin DB, Bonilla E. Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 1989; 50: 145-150.
141. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleepwake cycle and circadian timing in Huntington's disease. J Neurosci 2005; 25: 157-163.
142. Muller EE, Cocchi D, Mantegazza P, Parati EA, Caraceni T. Prolactin control in Huntington's chorea. Lancet 1977; ii: 764-765.
143. Muller EE, Parati EA, Cocchi D, Zanardi P, Caraceni T. Dopaminergic drugs on growth hormone and prolactin secretion in Huntington's disease. In: Chase TN, Wexler NS, Barbeau A, eds. Advances in Neurology. New York: Raven Press, 1979; 319-334.
144. Murri L, Iudice A, Muratorio A, Polleri A, Barreca T, Muriaido G. Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea. Eur Neurol 1980; 19: 198-206.
145. Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991; 48: 800-804.
146. Nance MA, Sanders G. Characteristics of individuals with Huntington disease in long-term care. Mov Disord 1996; 11: 542-548.
147. Nemeroff CB, Youngblood WW, Manberg PJ, Prange AJ Jr, Kizer JS. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science 1983; 221: 972-975.
148. Nillni EA, Sevarino KA. The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr Rev 1999; 20: 599-648.
149. Oepen H. [On 217 body dissection findings in Huntington's disease.]. Beitr Pathol Anat 1963; 128: 12-24.
150. Oepen H. Steroid metabolism and thrombocyte serotonin in Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology. New York: Raven Press, 1973; 551-552.
151. Oepen H, Landzettel HJ, Streletzkir von KOPP. [Statistical findings on the clinical aspects of Huntington's chorea.]. Arch Psychiatr Nervenkr Ζ Gesamte Neurol Psychiatr 1963; 204: 11-24.
152. Oepen H, Oepen I. [Amino acids in the blood in Huntington's chorea]. Humangenetik 1965; 1: 299-302.
153. Ottosson JO, Rapp W. Serum levels of phenylalanine and tyrosine in Huntington's chorea. Acta Psychiatr Scand Suppl 1971; 221: 89-91.
154. Ottosson JO, Rapp W. Amino acids in Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology. New York: Raven Press, 1973; 619-621.
155. Overeem S, Kok SW, Lammers GJ, Vein AA, Frolich M, Meinders AE, et al. Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. Am J Physiol Endocrinol Metab 2003; 284: E641-E647.
156. Papalexi E, Persson A, Bjorkqvist M, Petersen A, Woodman B, Bates GP, et al. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. Eur J Neurosci 2005; 22: 1541-1546.
157. Pascoe M. Huntington's disease and low tryptophan diet. Med Hypotheses 1993; 41: 325-326.
158. Paulson GW, Malarkey WB, Shaw G. Huntington's disease, INH, and prolactin levels. In: Chase TN, Wexler NS, Barbeau A, eds. Advances in Neurology. New York: Raven Press, 1979; 797-801.
159. Perry TL, Diamond S, Hansen S, Stedman D. Plasma-aminoacid levels in Huntington's chorea. Lancet 1969; i: 806-808.
160. Perry TL, Hansen S, Lesk D, Kloster M. Amino acids in plasma, cerebrospinal fluid, and brain of patients with Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology. New York: Raven Press, 1973; 609-618.
161. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 2006; 24: 961-967.
162. Petersen A, Gil J, Maat-Schieman ML, Bjorkqvist M, Tanila H, Araujo IM, et al. Orexin loss in Huntington's disease. Hum Mol Genet 2005; 14: 39-47.
163. Petersenn S. Growth hormone secretagogues and ghrelin: an update on physiology and clinical relevance. Horm Res 2002; 58 (Suppl 3): 56-61.
164. Petit D, Gagnon JF, Fantini ML, Ferini-Strambi L, Montplaisir J. Sleep and quantitative EEG in neurodegenerative disorders. J Psychosom Res 2004; 56: 487-496.
165. Phillipson OT, Bird ED. Plasma growth hormone concentrations in Huntington's chorea. Clin Sci Mol Med 1976; 50: 551-554.
166. Phillipson OT, Bird ED. Plasma glucose, non-esterified fatty acids and amino acids in Huntington's chorea. Clin Sci Mol Med 1977; 52: 311-318.
167. Podolsky S, Leopold NA. Growth hormone abnormalities in Huntington's chorea: effect of L-dopa administration. J Clin Endocrinol Metab 1974; 39: 36-39.
168. Podolsky S, Leopold NA. Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 1977; 23: 55-63.
169. Podolsky S, Leopold NA, Sax DS. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1972; i: 1356-1358.
170. Popovic V, Duntas LH. Leptin TRH and ghrelin: influence on energy homeostasis at rest and during exercise. Horm Metab Res 2005; 37: 533-537.
171. Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur J Endocrinol 2004; 151: 451-455.
172. Pratley RE, SaIbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol 2000; 47: 64-70.
173. Puri BK. Impaired phospholipid-related signal transduction in advanced Huntington's disease. Exp Physiol 2001; 86: 683-685.
174. Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. NeuroReport 2002; 13: 123-126.
175. Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005; 65: 286-292.
176. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994; 60: 436-444.
177. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry 1995; 152: 1372-1376.
178. Reed TE, Neel JV. Huntington's chorea in Michigan. 2. Selection and mutation. Am J Hum Genet 1959; 11: 107-136.
179. Reilmann R, Rolf LH, Lange HW. Decreased plasma alanine and isoleucine in Huntington's disease. Acta Neurol Scand 1995; 91: 222-224.
180. Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM, et al. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci 2004; 20: 3092-3114.
181. Robbins AO, Ho AK, Barker RA. Weight changes in Huntington's disease. Eur J Neurol 2006; 13: e7.
182. Roos RA, Bots GT, Hermans J. Neuronal nuclear membrane indentation and astrocyte/neuron ratio in Huntington's disease. A quantitative electron microscopic study. J Hirnforsch 1985; 26: 689-693.
183. Rossor MN, Hunt SP, Iversen LL, Bannister R, Hawthorn J, Ang VT, et al. Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease. Brain Res 1982; 253: 341-343.
184. Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005; 20: 674-679.
185. Sakai T, Antoku Y, Iwashita H, Goto I, Nagamatsu K, Shii H. Chorea-acanthocytosis: abnormal composition of covalently bound fatty acids of erythrocyte membrane proteins. Ann Neurol 1991; 29: 664-669.
186. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-585.
187. Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med J Aust 1981; 1: 407-409.
188. Schöpe Μ. Über Veränderungen im pyramidal-motorischen System bei einer Chorea Huntington. Ζ f d ges Neurologie u Psychiatrie 1940; 168: 679-684.
189. Schroeder F, Goetz IE, Roberts E. Membrane anomalies in Huntington's disease fibroblasts. J Neurochem 1984; 43: 526-539.
190. Schubotz R, Hausmann L, Kaffarnik H, Zehner J, Oepen H. [Fatty acid patterns and glucose tolerance in Huntington's chorea (author's transl)]. Res Exp Med (Berl) 1976; 167: 203-215.
191. Selemon LD, Rajkowska G, Goldman-Rakic PS. Evidence for progression in frontal cortical pathology m late-stage Huntington's disease. J Comp Neurol 2004; 468: 190-204.
192. Sharma KR, Romano JG, Ayyar DR, Rotta FT, Facca A, Sanchez-Ramos J. Sympathetic skin response and heart rate variability in patients with Huntington disease. Arch Neurol 1999; 56: 1248-1252.
193. Sharp AH, Ross CA. Neurobiology of Huntington's disease. Neurobiol Dis 1996; 3: 3-15.
194. Sheng G, Chang GQ, Lin JY, Yu ZX, Fang ZH, Rong J, et al. Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior. Nat Med 2006; 12: 526-533.
195. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998; 396: 670-674.
196. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979; 29: 1-3.
197. Shoulson I, Miller C, Welle S, Panzik J, Lipinski B, Plumb S, Forbes G. Huntington's disease: body weight and basal metabolic indices. Ann Neurol 1984; 16: 126.
198. Siegel JM. The neurotransmitters of sleep. J Clin Psychiatry 2004; 65 (Suppl 16): 4-7.
199. Silvestri R, Raffaele M, DeDomenico P, Tisano A, Mento G, Casella C, et al. Sleep features in Tourette's syndrome, neuroacanthocytosis and Huntington's chorea. Neurophysiol Clin 1995; 25: 66-77.
200. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 2002; 11: 1953-1965.
201. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA 2005; 102: 11402-11407.
202. Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 2005; 93: 611-623.
203. Stoy N, McKay E. Weight loss in Huntington's disease. Ann Neurol 2000; 48: 130-131.
204. Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C, et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 2005; 14: 1863-1876.
205. Sumbilla C, Lakowicz JR. Fluorescence studies of red blood cell membranes from individuals with Huntington's disease. J Neurochem 1982; 38: 1699-1708.
206. Sumbilla C, Lakowicz JR. Evidence for normal fibroblast cell membranes from individuals with Huntington's disease. A fluorescence probe study. J Neurol Sci 1983; 62: 23-40.
207. Swaab DF. The human hypothalamus: basic and clinical aspects, part I: nuclei of the human hypothalamus. In: Aminoff MJ, Boller F, Swaab DF, eds. Handbook of Clinical Neurology, Vol. 79. Amsterdam: Elsevier, 2003.
208. Swaab DF. The human hypothalamus: basic and clinical aspects, part II: neuropathology of the human hypothalamus and adjacent structures. In: Aminoff MJ, Boller F, Swaab DF, eds. Handbook of Clinical Neurology, Vol. 80. Amsterdam: Elsevier, 2004.
209. Tamminga CA, Neophytides A, Chase TN, Frohman LA. Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. J Clin Endocrinol Metab 1978; 47: 1348-1351.
210. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10: 148-154.
211. Tanaka M, Machida Y, Nukina N. A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules. J Mol Med 2005; 83: 343-352.
212. Taylor N, Bramble D. Sleep disturbance and Huntingdon's disease. Br J Psychiatry 1997; 171: 393.
213. Timmers HJ, Swaab DF, van de Nes JA, Kremer HP. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients. Brain Res 1996; 728: 141-148.
214. Tokita S, Takahashi K, Kotani H. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sei 2006; 101: 12-18.
215. Trejo A, Boll MC, Alonso ME, Ochoa A, Velasquez L. Use of oral nutritional supplements in patients with Huntington's disease. Nutrition 2005; 21: 889-894.
216. Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 2004; 20: 192-196.
217. Tyler-McMahon BM, Boules M, Richelson E. Neurotensin: peptide for the next millennium. Regul Pept 2000; 93: 125-136.
218. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006; 129: 877-886.
219. Unger JW, Lange W. Immunohistochemical mapping of neurophysins and calcitonin gene-related peptide in the human brainstem and cervical spinal cord. J Chem Neuroanat 1991; 4: 299-309.
220. Unmehopa UA, van Heerikhuize JJ, Spijkstra W, Woods JW, Howard AD, Zycband E, et al. Increased melanin concentrating hormone receptor type I in the human hypothalamic infundibular nucleus in cachexia. J Clin Endocrinol Metab 2005; 90: 2412-2419.
221. Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. NeuroReport 2002; 13: 29-33.
222. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005; 25: 9932-9939.
223. Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, et al. Body weight is modulated by levels of full-length Huntingtin. Hum Mol Genet 2006; 15: 1513-1523.
224. Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 2005; 196: 266-272.
225. van Zwieten EJ, Ravid R, Hoogendijk WJ, Swaab DF. Stable vasopressin innervation in the degenerating human locus coeruleus in Alzheimer's disease. Brain Res 1994; 649: 329-333.
226. Veldhuis JD, Johnson ML. Analytical methods for evaluating episodic secretory activity within neuroendocrine axes. Neurosci Biobehav Rev 1994; 18: 605-612.
227. Vogt C, Vogt O. Precipitating and modifying agents in chorea. J Nerv Ment Dis 1952; 116: 601-607.
228. Wahren W. Anatomy of the hypothalamus. In: Schaltenbrand G, Bailey P, eds. Introduction of Stereotaxis with an Atlas of the Human Brain. Stuttgart: Thieme, 1959; 119-151.
229. Wahren W. Zur Pathoklise des Nucleus Tuberis lateralis. Prog Brain Res 1964; 5: 161-170.
230. Wherrett JR, Brown BL. Erythrocyte glycolipids in Huntington's chorea. Neurology 1969; 19: 489-493.
231. Wiegand M, Moller AA, Lauer CJ, Stolz S, Schreiber W, Dose M, et al. Nocturnal sleep in Huntington's disease. J Neurol 1991; 238: 203-208.
232. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001; 24: 429-458.
233. Wisse BE, Ogimoto K, Schwartz MW. Role of hypothalamic interleukin-1beta (IL-1 beta) in regulation of energy homeostasis by melanocortins. Peptides 2006; 27: 265-273.
234. Wisse BE, Schwartz MW, Cummings DE. Melanocortin signaling and anorexia in chronic disease states. Ann NY Acad Sci 2003; 994: 275-281.
235. Wood JH, Ziegler MG, Lake CR, Shoulson I, Brooks BR, Van Buren JM. Cerebrospinal fluid norepinephrine reductions in man after degeneration and electrical stimulation of the caudate nucleus. Ann Neurol 1977; 1: 94-99.
236. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol 2005; 184: 291-318.
237. Yates CM, Magill BE, Davidson D, Murray LG, Wilson H, Pullar IA. Lysosomal enzymes, amino acids and acid metabolites of amines in Huntington's chorea. Clin Chim Acta 1973; 44: 139-145.